Immunic (IMUX) said Wednesday that interim data from a phase 2 trial show the potential effectiveness of its experimental drug vidofludimus calcium in progressive multiple sclerosis.
The company said the investigational drug was found to reduce neurofilament light chain levels compared with placebo in the study.
The company also said antiviral data suggested that the drug may reduce fatigue while preclinical data indicated that vidofludimus calcium promotes neuronal survival through the activation of nuclear receptor related 1, or Nurr1, and pathogenic T cell data support the drug's anti-inflammatory effects.
The data will be presented this week at a conference in Copenhagen, Denmark, Immunic said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。